Not yet a member?Join now!|Lost password
05/25/2012 | Press release
distributed by noodls on 05/25/2012 21:04
SEATTLE--(BUSINESS WIRE)-- May 25, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the following conferences:
The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
Dendreon Corporation
Investor Relations:
Nicole Soley, 206-455-2220
InvestorRelations@dendreon.com
Source: Dendreon Corporation
News Provided by Acquire Media